Ipsen SA News - I7G

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024 Aggregated presentation by day and by market Purchases of own shares from June...

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024 Aggregated presentation by day and by market Purchases of own shares from June...

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024 Aggregated presentation by day and by market Statement of transactions in own...

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis ...

Ipsen et Marengo Therapeutics annoncent la conclusion d’un second partenariat stratégique afin de faire progresser les actifs « T-Cell Engager » de précision de la plateforme TriSTAR de Marengo

Ipsen et Marengo Therapeutics annoncent la conclusion d’un second partenariat stratégique afin de faire progresser les actifs « T-Cell...

Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social Information mensuelle...

Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer

Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer PARIS, FRANCE, 06 June 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a...

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis New data...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Ipsen SA (I7G)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

I7G News

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Ipsen et Marengo Therapeutics annoncent la conclusion d’un second partenariat stratégique afin de faire progresser les actifs « T-Cell Engager » de précision de la plateforme TriSTAR de Marengo

Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

I7G Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Ipsen SA (I7G) News

Ipsen SA (I7G)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

I7G News

IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Ipsen et Marengo Therapeutics annoncent la conclusion d’un second partenariat stratégique afin de faire progresser les actifs « T-Cell Engager » de précision de la plateforme TriSTAR de Marengo

Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer

Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

I7G Discussion

Your Recent History